BioCentury | Sep 12, 2011
Company News
Evec, Astellas deal
...exclusive, worldwide rights to develop and commercialize one of Evec's preclinical antibodies against infectious diseases. Evec...
...receive up to ¥13 billion ($169 million) in milestones, plus royalties. Details were not disclosed. Evec Inc....
...receive up to ¥13 billion ($169 million) in milestones, plus royalties. Details were not disclosed. Evec Inc....
